Company intelligence / Profile preview
Lochhead Scientific
- Ownership
- Private
- Development stage
- Other
Overview
Lochhead Scientific is in the pre-clinical development stage for a novel Lyme disease vaccine. Recent efforts have focused on the synthesis of a two-component conjugate vaccine candidate that combines the Outer surface protein A (OspA) with a highly immunogenic T-cell antigen derived from the methyl-accepting transducer domain (MATD) of the Borrelia burgdorferi chemotaxis protein Mcp4. Pre-clinical research conducted in collaboration with the Medical College of Wisconsin has identified this MATD-derived epitope as a potent CD4+ T-cell antigen that generates robust immune responses in mouse models.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineRecombinant protein
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Lochhead Scientific.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lochhead Scientific.